Erica Farrar, PA
Medical · Douglasville, GANPI 1962574939
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 479 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,991, 3.9 times the $772 reported in 2021. Among medical clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 479 payments — averaging $20.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Sanofi$1K
- Boehringer Ingelheim$995
- Grifols USA, LLC$670
- Electromed, Inc.$477
- plus $3K from 29 others
What the payments were for
- Food & beverage$9,914100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 123 | $2,359 |
| AstraZeneca(2 entities) | 65 | $1,281 |
| Sanofi | 47 | $1,224 |
| Boehringer Ingelheim | 45 | $995 |
| Grifols USA, LLC | 32 | $670 |
| Electromed, Inc. | 38 | $477 |
| Regeneron Healthcare Solutions, Inc. | 17 | $465 |
| Mylan Specialty L.p. | 11 | $264 |
| Actelion Pharmaceuticals US, Inc. | 9 | $201 |
| Amgen | 10 | $194 |
| Verona Pharma, Inc. | 6 | $184 |
| ANI Pharmaceuticals, Inc. | 9 | $184 |
| United Therapeutics Corporation | 7 | $169 |
| Insmed, Inc. | 7 | $151 |
| Mallinckrodt Hospital Products Inc. | 5 | $143 |
| Pulmonx Corporation | 5 | $123 |
| Baxter Healthcare | 4 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $89 |
| Inogen, Inc. | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 5 | $74 |
| CSL Behring | 3 | $74 |
| Viatris Specialty LLC | 3 | $69 |
| Novartis | 3 | $56 |
| Pfizer | 3 | $55 |
| Bayer | 2 | $37 |
| Merck | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $28 |
| Fisher & Paykel Healthcare Inc | 1 | $27 |
| 3b Medical, Inc. | 1 | $26 |
| Gilead | 1 | $18 |
| Advanced Respiratory, Inc | 1 | $17 |
| Resmed Corp | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Breas Medical, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,930 in reported general payments places this provider in the 90th percentile of 950 medical providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 233 | $171,388 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $59,991 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $41,436 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $28,108 |
| Spiriva RespimatTiotropium Bromide | 37 | $28,024 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 53 | $27,835 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 358 | $10,910 |
| EliquisApixaban | 15 | $8,673 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $8,358 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $5,619 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 14 | $5,536 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $4,709 |
| Arnuity ElliptaFluticasone Furoate | 12 | $4,415 |
| Ventolin HfaAlbuterol Sulfate | 46 | $3,731 |
| Roflumilast | 17 | $2,497 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,359 | $231,745364 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,281 | $71,145120 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $995 | $69,46199 claims |
| PfizerEliquis | $55 | $8,67315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 950 medical providers in Georgia.
Other medical in Douglasville
- Tomas ChaoWoodstock$1.9M
- Kimberly OrleckAtlanta$727K
- Audrey GibsonGainesville$302K
- Lisa WeissCanton$283K
- Laura BushFayetteville$146K
- Michael KelleherMarietta$126K
- Juliena GigonMarietta$122K
- Felicia HoffmanRoswell$114K
- Sally BrumbillLithia Springs$110K
- Danna Dennis-CalderAtlanta$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.